Treatment with TREK1 and TRPC3/6 ion channel inhibitors upregulates microRNA expression in a mouse model of chronic mild stress
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Depression is a common mental disorder characterized by the mood of deep sadness. Recent studies have demonstrated that microRNAs and ion channels have significant roles in the etiopathogenesis of depression. Therefore, we investigated the effects of the TREK1 ion channel inhibitor anandamide and the TRPC3/6 inhibitor norgestimate on microRNA expression and antidepressant effect in the mouse chronic mild stress (CMS) model of depression. Male BALB/c mice were divided into groups as control, CMS, CMS+sertraline, CMS+anandamide, CMS+sertraline+anandamide, CMS+norgestimate and CMS+sertraline+norgestimate. Forced swim test (FST) and Sucrose Preference Test (SPT) were utilized to assess depression levels. Anandamide and norgestimate were administered subcutaneously (5mg/kg/day), and sertraline was applied intraperitoneally (10mg/kg/day) for two days during FST. miRNA and ion channel gene expression levels in the prefrontal cortex were assessed with qRT-PCR. qRT-PCR results demonstrated that there was a significant increase in miR-9-5p, miR-128-1-5p, and miR-382-5p, and a significant decrease in miR-16-5p, miR-129-5p, and miR-219a-5p in the CMS group compared with the control group. Generally, anandamide and norgestimate significantly increased all miRNA expression. It was also determined that anandamide and norgestimate had an antidepressant action in FST when used alone and especially when used in conjunction with sertraline. Based on the study results, it could be argued that an increase in miR-9-5p and miR-128-1-5p, consistent with the literature, could play significant roles in the etiopathogenesis of depression. The antidepressant action of anandamide and norgesimate in FST showed for the first time that these inhibitors could be used as in conjuction with sertraline in depression treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Willner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · cited 1×
“In the present study, a CMS protocol was designed with various modifications based on the studies of Wilner [18].”
Major depressive disorder: new clinical, neurobiological, and treatment perspectives
Kupfer, D. J., Frank, E., & Phillips, M. L. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60602-8 · Cited by 894 · cited 1×
“Major depressive disorder (MDD) is a prevalent disease worldwide and has serious negative effects on quality of life [1].”
Animal models of major depression and their clinical implications
Czéh, B., Fuchs, E., Wiborg, O., & Simon, M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.04.004 · Cited by 375 · cited 1×
“Chronic mild stress is a reliable animal model, often utilized in depression studies, where basic symptoms of depression could realistically be observed [24].”
Blood microRNA changes in depressed patients during antidepressant treatment
Bocchio-Chiavetto, L., Maffioletti, E., Bettinsoli, P., Giovannini, C., Bignotti, S., Tardito, D., Corrada, D., Milanesi, L., & Gennarelli, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.013 · Cited by 238
Rollema, H., Guanowsky, V., Mineur, Y. S., Shrikhande, A., Coe, J. W., Seymour, P. A., & Picciotto, M. R. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.01.002 · Cited by 87
Takahashi, T., Kobayashi, T., Ozaki, M., Takamatsu, Y., Ogai, Y., Ohta, M., Yamamoto, H., & Ikeda, K. (2006) · Neuroscience Research · doi:10.1016/j.neures.2005.10.012 · Cited by 22 · cited 13×
“Some preclinical studies have demonstrated that certain potassium channel inhibitors such as tetraethyl ammonium (TEA), apamin, charybdotoxin, gliquidone, glibenclamide, and the calcium channel inhibitor nifedipine had strong antidepressant action in a forced swimming test (FST) [5].”
Influential
Cited by
Zhang, Y., Du, L., Bai, Y., Han, B., He, C., Gong, L., Huang, R., Shen, L., Chao, J., Liu, P., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0285-0 · Cited by 184
Non-coding RNAs in depression: Promising diagnostic and therapeutic biomarkers
Shi, Y., Wang, Q., Song, R., Kong, Y., & Zhang, Z. (2021) · eBioMedicine · doi:10.1016/j.ebiom.2021.103569 · Cited by 79
He, C., Bai, Y., Wang, Z., Fan, D., Wang, Q., Liu, X., Zhang, H., Zhang, H., Zhang, Z., Yao, H., et al. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2020.117428 · Cited by 44
Bortolozzi, A., Manashirov, S., Chen, A., & Artigas, F. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107873 · Cited by 37
miRNAs in depression vulnerability and resilience: novel targets for preventive strategies
Lopizzo, N., Zonca, V., Cattane, N., Pariante, C. M., & Cattaneo, A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02048-2 · Cited by 37
Metadata
- Authors
- Buran, İ., Etem, E. Ö., Tektemur, A., & Elyas, H.
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 656
- Pages
- 51-57
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2735985713
- Cited by
- 35
- References
- 6
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment with TREK1 and TRPC3/6 ion channel inhibitors upregulates microRNA expression in a mouse model of chronic mild stress. https://app.cochat.ai/papers/10.1016/j.neulet.2017.07.017
- The paper
- Buran, İ., Etem, E. Ö., Tektemur, A., & Elyas, H. (2017). Treatment with TREK1 and TRPC3/6 ion channel inhibitors upregulates microRNA expression in a mouse model of chronic mild stress. Neuroscience Letters. https://doi.org/10.1016/j.neulet.2017.07.017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.